naltrexone has been researched along with sertraline in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 15 (65.22) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Farren, CK; O'Malley, S | 1 |
| Oslin, DW | 1 |
| Deas, D; Dosh, T; Kazura, A; Kratochvil, CJ; Martin, CA; Wilens, TE | 1 |
| Chance, LE; Goldman, D; GreyWolf, I; Hodgkinson, CA; Levenson, AL; Meandzija, B; O'Malley, SS; Robin, RW; Robinson, J; Romano, D; Stillner, V; Wu, R | 1 |
| Farren, CK; Malley, SO; Scimeca, M; Wu, R | 1 |
| Gopalakrishnan, R; O'Brien, C; Oslin, D; Ross, J | 1 |
| Dackis, CA; Dundon, WD; Gallis, TL; Kampman, KM; O'Brien, CP; Oslin, DW; Pettinati, HM; Xie, H | 1 |
| Li, TK; Patkar, AA | 1 |
| O'Brien, CP | 1 |
| Dundon, WD; O'Brien, CP; Pettinati, HM | 1 |
| Mittal, A | 1 |
| Alpert, JE; Baer, L; Clain, AJ; Cusin, C; Fava, M; Hylek, L; Ionescu, DF; Mischoulon, D; Soskin, DP; Yeung, AS | 1 |
| Le Foll, B; Samokhvalov, AV | 1 |
| de Jong, J; Neven, A; Pieterse, BH | 1 |
| Gasparyan, A; Manzanares, J; Navarrete, F | 1 |
4 review(s) available for naltrexone and sertraline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Current status of co-occurring mood and substance use disorders: a new therapeutic target.
Topics: Alcoholism; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Diagnosis, Dual (Psychiatry); Double-Blind Method; Drug Therapy, Combination; Humans; Mood Disorders; Naltrexone; Narcotic Antagonists; Psychotropic Drugs; Sertraline; Substance-Related Disorders | 2013 |
Cholestatic Itch Management.
Topics: Anion Exchange Resins; Cholagogues and Choleretics; Cholestasis; Cholestyramine Resin; Humans; Lysophospholipids; Naltrexone; Narcotic Antagonists; Plasmapheresis; Pregnane X Receptor; Pruritus; Receptors, Steroid; Rifampin; Selective Serotonin Reuptake Inhibitors; Sertraline; Ultraviolet Therapy; Ursodeoxycholic Acid | 2016 |
[The pharmacological treatment of PTSD and alcohol use disorder: a systematic literature review].
Topics: Alcohol-Related Disorders; Disulfiram; Drug Therapy, Combination; Humans; Naltrexone; Randomized Controlled Trials as Topic; Sertraline; Stress Disorders, Post-Traumatic | 2019 |
7 trial(s) available for naltrexone and sertraline
| Article | Year |
|---|---|
A pilot double blind placebo controlled trial of sertraline with naltrexone in the treatment of opiate dependence.
Topics: Adult; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pilot Projects; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Treatment of late-life depression complicated by alcohol dependence.
Topics: Age of Onset; Aged; Alcoholism; Antidepressive Agents; Depressive Disorder, Major; Empathy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Sertraline; Social Support | 2005 |
Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial.
Topics: Adult; Alaska; Alcoholism; Drug Therapy, Combination; Female; Humans; Indians, North American; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Polymorphism, Genetic; Receptors, Opioid, mu; Rural Population; Selective Serotonin Reuptake Inhibitors; Sertraline | 2008 |
A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence.
Topics: Adult; Age of Onset; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Ethnicity; Female; Humans; Male; Marital Status; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Patient Selection; Psychiatric Status Rating Scales; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2009 |
Course of late-life depression with alcoholism following combination therapy.
Topics: Aging; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Middle Aged; Naltrexone; Placebos; Sertraline; Severity of Illness Index; Treatment Outcome | 2009 |
A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.
Topics: Adult; Alcoholism; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Naltrexone; Selective Serotonin Reuptake Inhibitors; Sertraline | 2010 |
Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants.
Topics: Adult; Antidepressive Agents; Aripiprazole; Central Nervous System Stimulants; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Sertraline; Treatment Outcome | 2017 |
12 other study(ies) available for naltrexone and sertraline
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Pharmacological management of a teen with significant alcohol use and depression.
Topics: Adolescent; Alcoholism; Antidepressive Agents; Depression; Female; Humans; Naltrexone; Narcotic Antagonists; Sertraline | 2006 |
Treatments for alcohol dependence: rethinking the role of comorbidity and clinical subtypes.
Topics: Alcoholism; Cognitive Behavioral Therapy; Comorbidity; Depressive Disorder, Major; Humans; Naltrexone; Selective Serotonin Reuptake Inhibitors; Sertraline | 2010 |
Adapting treatment to patient problems.
Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug Therapy, Combination; Gabapentin; gamma-Aminobutyric Acid; Humans; Naltrexone; Research Design; Sertraline | 2011 |
A 35-year-old woman with low mood and concerns about her alcohol use.
Topics: Adult; Alcoholism; Antidepressive Agents; Counseling; Depressive Disorder, Major; Female; Humans; Naltrexone; Narcotic Antagonists; Patient Care Planning; Sertraline | 2017 |
The administration of sertraline plus naltrexone reduces ethanol consumption and motivation in a long-lasting animal model of post-traumatic stress disorder.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Antidepressive Agents; Disease Models, Animal; Drug Therapy, Combination; Male; Mice; Mice, Inbred C57BL; Motivation; Naltrexone; Self Administration; Serotonin Plasma Membrane Transport Proteins; Sertraline; Stress Disorders, Post-Traumatic; Stress, Psychological; Time Factors | 2021 |